HLA-A and non-small cell lung carcinoma: IMA203, an autologous TCR-engineered therapy, uses a novel, pairing-enhanced TCR with high affinity and specificity for the HLA-A*02:01-presented peptide related to PRAME, a potential target for multiple solid tumors including NSCLC.